<bill session="110" type="h" number="3264" updated="2013-07-19T21:32:34-04:00">
  <state datetime="2007-07-31">REFERRED</state>
  <status>
    <introduced datetime="2007-07-31"/>
  </status>
  <introduced datetime="2007-07-31"/>
  <titles>
    <title as="introduced" type="short">American Life Sciences Competitiveness Act of 2007</title>
    <title as="introduced" type="official">To amend the Internal Revenue Code of 1986 to modernize the tax treatment of biomedical research corporations.</title>
  </titles>
  <sponsor id="400647"/>
  <cosponsors>
    <cosponsor id="400046" joined="2007-07-31"/>
    <cosponsor id="400176" joined="2007-07-31"/>
    <cosponsor id="400291" joined="2007-07-31"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2007-07-31">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
    <action datetime="2007-08-02">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR E1689-1690"/>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Biomedical engineering"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Finance and financial sector"/>
    <term name="Health"/>
    <term name="Income tax"/>
    <term name="Investment tax credit"/>
    <term name="Investments"/>
    <term name="Losses"/>
    <term name="Medical research"/>
    <term name="Orphan drugs"/>
    <term name="Pharmaceutical research"/>
    <term name="Research and development tax credit"/>
    <term name="Science, technology, communications"/>
    <term name="Small business"/>
    <term name="Tax credits"/>
    <term name="Tax deductions"/>
    <term name="Tax deferral"/>
  </subjects>
  <amendments/>
  <summary>7/31/2007--Introduced.
American Life Sciences Competitiveness Act of 2007 - Amends the Internal Revenue Code to allow biomedical research corporations to: (1) engage in investment activity involving shifts in ownership without incurring limitations on net operating loss carryforwards; (2) claim a full research and development tax credit for contract research expenses (currently, limited to 65%); (3) claim a business tax credit for 20% of eligible countermeasures research expenses (for biomedical threats); and (4) claim a tax-free rollover of gain from stock sales reinvested in another biomedical research corporation.Expands the tax credit for clinical testing expenses for drugs to treat rare diseases (orphan drugs) to include expenses incurred after an application is made to the Food and Drug Administration (FDA) but before receipt of an orphan drug designation.Allows individual taxpayers a 20% tax credit for equity investments in small biomedical research firms engaged in incubational research (i.e., research conducted prior to large-scale clinical trials).</summary>
</bill>
